Genedx Holdings CORP

GeneDx Holdings Corp. announced its second quarter 2026 financial results, highlighting an 11% year-over-year revenue increase to $114.4 million and a 32% surge in exome and genome test volume.

GeneDx Holdings Corp. announced the appointment of Mark Gardner as President, effective June 15, 2026, to lead commercial and operations teams.

GeneDx Holdings Corp. announced its first quarter 2026 financial results, reporting revenue growth and updating its full-year guidance with a focus on profitability.

GeneDx Holdings Corp. entered a new $100 million term loan agreement with Blackstone, repaying its previous debt and aiming for balance sheet optimization.

GeneDx Holdings Corp. reported robust fourth quarter and full year 2025 financial results, surpassing revenue guidance and reaffirming strong growth projections for 2026 driven by exome and genome testing.

GeneDx Holdings Corp. announced preliminary 2025 financial results at the high end of or exceeding guidance and issued robust growth projections for 2026.

GeneDx Holdings Corp. announced its Q2 2026 financial results, showing an 11% increase in total revenue to $114.4 million, but also a net loss of $17.7 million.

GeneDx Holdings Corp. reported significant revenue growth and reduced net losses for the third quarter and first nine months of 2025, driven by increased diagnostic test volumes and the acquisition of Fabric Genomics.

GeneDx Holdings Corp. reported a significant financial turnaround in the second quarter of 2025, moving from a net loss to a net income and generating positive operating cash flow, fueled by a substantial increase in diagnostic test revenue and the integration of Fabric Genomics.

GeneDx Holdings Corp. announces a 40% increase in total revenue for the first quarter of 2025, primarily driven by growth in exome and genome sequencing revenues.

GeneDx Holdings Corp. saw a significant increase in revenue during the third quarter of 2024, primarily driven by higher diagnostic test volumes and improved reimbursement rates.

GeneDx Holdings Corp. saw a significant increase in revenue during the second quarter of 2024, primarily driven by higher demand for its whole exome and genome sequencing services.

GeneDx Holdings Corp. announced a 40% increase in total revenue for fiscal year 2025, driven by exome and genome sequencing, while also disclosing a material weakness in internal control over financial reporting.

GeneDx Holdings Corp. demonstrates significant revenue increase in 2024, driven by exome and genome sequencing, while navigating regulatory changes and strategic realignments.

GeneDx Holdings Corp.'s 10-K filing provides a detailed description of its registered securities, including common stock, preferred stock, and warrants.

GeneDx Holdings Corp. reports that President Mark A. Gardner was granted 35,441 restricted stock units on June 29, 2026.

GeneDx Holdings Corp. reports that Chief Financial Officer Kevin Feeley sold shares to cover tax obligations related to RSU vesting.

Katherine Stueland, CEO and Director of GeneDx Holdings Corp., reported the sale of 8,501 shares of Class A Common Stock to cover tax withholding obligations upon the vesting of restricted stock units.

GeneDx Holdings Corp. CFO Kevin Feeley reports on stock transactions, including RSU vesting and sale to cover tax obligations.

Katherine Stueland, CEO of GeneDx Holdings Corp., reported transactions involving Class A Common Stock and Restricted Stock Units.

Casdin Capital, LLC and Eli Casdin have increased their beneficial ownership in GeneDx Holdings Corp. through recent open market purchases.

GeneDx Holdings Corp. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 18, 2026.

Genedx Holdings Corp. files a definitive proxy statement with the SEC.

GeneDx Holdings Corp. will hold its 2025 annual meeting of stockholders virtually on June 18, 2025, to elect directors and ratify the appointment of its independent auditor.

Genedx Holdings Corp. has filed a definitive proxy statement with the SEC.

GeneDx Holdings Corp. will hold its 2024 annual meeting of stockholders on June 20, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the company's independent auditor.

Casdin Partners Master Fund acquired 500,000 shares of GeneDx Holdings Corp. between May 18 and May 20, 2026.

Corvex Management LP and affiliated entities have increased their stake in GeneDx Holdings Corp. through open market purchases.

Key investors Eli Casdin and Keith Meister, through their respective entities, have significantly increased their beneficial ownership in GeneDx Holdings Corp.

A group including Eli Casdin and Keith Meister reported a reduction in their beneficial ownership of GeneDx Holdings Corp. Class A common stock through an open market sale.

A group of significant investors, including Eli Casdin and Keith Meister, have increased their beneficial ownership in GeneDx Holdings Corp., with their collective stake now reaching up to 14.2% of Class A common stock.

Icahn School of Medicine at Mount Sinai and Mount Sinai Health System, Inc. have completed sales of GeneDx Holdings Corp. Class A Common Stock, reducing their collective beneficial ownership below 5% and filing their final Schedule 13D amendment.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 5.8% of GenEdx Holdings Corp.'s Class A common stock as of June 30, 2026.

ARK Investment Management LLC, led by Catherine D. Wood, has reported beneficial ownership of 5.33% of GeneDx Holdings Corp.'s common stock, signaling a notable investment position.

BlackRock, Inc. has reported a beneficial ownership of 5.5% in GeneDx Holdings Corp. Class A Stock, as of June 30, 2026.

William Blair Investment Management, LLC has reported a 4.3% beneficial ownership stake in GeneDx Holdings Corp. common stock.

Summit Partners and its affiliates have disclosed a 3.04% beneficial ownership stake in GeneDx Holdings Corp. Class A common stock, totaling 867,265 shares.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing beneficial ownership of 0.6% of GeneDx Holdings Corp.'s Class A Common Stock as of June 30, 2025.